| Title |
Chinese medicine combined with calcipotriol betamethasone and calcipotriol ointment for Psoriasis vulgaris (CMCBCOP): study protocol for a randomized controlled trial
|
|---|---|
| Published in |
Trials, July 2014
|
| DOI | 10.1186/1745-6215-15-294 |
| Pubmed ID | |
| Authors |
Ze-Huai Wen, Mei-Ling Xuan, Yu-Hong Yan, Xiao-Yan Li, Dan-Ni Yao, Geng Li, Xin-Feng Guo, Ai-Hua Ou, Chuan-Jian Lu |
| Abstract |
Psoriasis causes worldwide concern because of its high-prevalence, as well as its harmful, and incurable characteristics. Topical therapy is a conventional treatment for psoriasis vulgaris. Chinese medicine (CM) has been commonly used in an integrative way for psoriasis patients for many years. Some CM therapies have shown therapeutic effects for psoriasis vulgaris (PV), including relieving symptoms and improving quality of life, and may reduce the relapse rate. However, explicit evidence has not yet been obtained. The purpose of the present trial is to examine the efficacy and safety of the YXBCM01 granule, a compound Chinese herbal medicine, with a combination of topical therapy for PV patients. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 35 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Denmark | 1 | 3% |
| Brazil | 1 | 3% |
| Unknown | 33 | 94% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 6 | 17% |
| Student > Ph. D. Student | 4 | 11% |
| Student > Bachelor | 3 | 9% |
| Lecturer | 2 | 6% |
| Lecturer > Senior Lecturer | 2 | 6% |
| Other | 5 | 14% |
| Unknown | 13 | 37% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 13 | 37% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 9% |
| Business, Management and Accounting | 1 | 3% |
| Biochemistry, Genetics and Molecular Biology | 1 | 3% |
| Psychology | 1 | 3% |
| Other | 1 | 3% |
| Unknown | 15 | 43% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 October 2015.
All research outputs
#17,729,864
of 25,986,827 outputs
Outputs from Trials
#24
of 45 outputs
Outputs of similar age
#144,671
of 240,674 outputs
Outputs of similar age from Trials
#32
of 43 outputs
Altmetric has tracked 25,986,827 research outputs across all sources so far. This one is in the 21st percentile – i.e., 21% of other outputs scored the same or lower than it.
So far Altmetric has tracked 45 research outputs from this source. They receive a mean Attention Score of 5.0. This one scored the same or higher as 21 of them.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 240,674 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 30th percentile – i.e., 30% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 43 others from the same source and published within six weeks on either side of this one. This one is in the 18th percentile – i.e., 18% of its contemporaries scored the same or lower than it.